OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells, which are derived from unfertilized human eggs, is working with tissue engineers at Cytograft Tissue Engineering, (Novato, CA), to design a custom cell culture medium to cultivate living human vascular grafts; grafts which are expected to be used in future human clinical trials.
